Shares of Inflarx NV (NASDAQ:IFRX) have been assigned an average recommendation of “Hold” from the eleven brokerages that are presently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $6.20.

Separately, Zacks Investment Research lowered shares of Inflarx from a “buy” rating to a “hold” rating in a research note on Wednesday, October 23rd.

IFRX traded down $0.10 during trading on Thursday, hitting $3.46. 9,098 shares of the company traded hands, compared to its average volume of 1,175,168. Inflarx has a one year low of $2.17 and a one year high of $53.10. The stock’s fifty day moving average is $2.63 and its 200 day moving average is $6.48. The firm has a market cap of $88.28 million, a P/E ratio of -2.43 and a beta of -1.27.

Several hedge funds have recently bought and sold shares of IFRX. FMR LLC purchased a new position in Inflarx in the 1st quarter valued at approximately $9,609,000. FNY Investment Advisers LLC purchased a new position in shares of Inflarx in the second quarter valued at $884,000. Acadian Asset Management LLC purchased a new position in shares of Inflarx in the second quarter valued at $445,000. Atria Investments LLC bought a new stake in shares of Inflarx during the 2nd quarter valued at $297,000. Finally, A.R.T. Advisors LLC raised its stake in shares of Inflarx by 145.8% during the 2nd quarter. A.R.T. Advisors LLC now owns 29,162 shares of the company’s stock valued at $92,000 after purchasing an additional 17,300 shares during the period. Institutional investors own 17.49% of the company’s stock.

Inflarx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.

Read More: What is the Dividend Aristocrat Index?

Analyst Recommendations for Inflarx (NASDAQ:IFRX)

Receive News & Ratings for Inflarx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inflarx and related companies with's FREE daily email newsletter.